Article
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Oncotarget - 26 Jul 2016
Wang Yuehong, Singh Ratnakar, Wang Liguang, Nilsson Monique, Goonatilake Ruchitha, Tong Pan, Li Lerong, Giri Uma, Villalobos Pamela, Mino Barbara, Rodriguez-Canales Jaime, Wistuba Ignacio, Wang Jing, Heymach John V, Johnson Faye M
Abstract excerpt
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective against non-small cell lung cancer (NSCLC) with activating EGFR mutations, but resistance is inevitable. Mechanisms of acquired resistance include T790M mutations and epithelial-mesenchymal transition (EMT). One potential strategy for overcoming this resistance is the inhibition of polo-like kinase 1 (PLK1) based on our...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.